Market Access VCs upbeat about European life sciences market, despite unce... It has been a curious start to the year for pharma and biotech investment.
Market Access EAPs: Market access outside of the US and Western Europe In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals about early access programmes.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
Market Access Health equity can be a competitive advantage: What pharma le... As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have a chance to lead – aligning innovation with access drivers and g
Market Access Unpacking Trump’s executive order on drug pricing, with Alic... Jonah Comstock welcomed back Alice Valder Curran to the podcast to pick apart Trump's Executive Order order piece by piece.
Market Access Buyer’s remorse: The UK’s VPAG With the ABPI wanting to change the scheme just over a year into its five-year term, it seems that they have buyer’s remorse.
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.
